Ovide

Ovide is a brand name of malathion topical, approved by the FDA in the following formulation(s):

OVIDE (malathion - lotion; topical)

• 
  Manufacturer: TARO PHARMS NORTH
  
  Approval date: August 2, 1982
  
  Strength(s): 0.5% ^[RLD][AT]

Has a generic version of Ovide been approved?

A generic version of Ovide has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ovide and have been approved by the FDA:

malathion lotion; topical

• 
  Manufacturer: SYNERX PHARMA
  
  Approval date: March 6, 2009
  
  Strength(s): 0.5% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ovide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Process for preparing malathion for pharmaceutical use
  Patent 7,560,445
  Issued: July 14, 2009
  Inventor(s): Gutman; Daniella & Baidussi; Wael
  Assignee(s): Taro Pharmaceuticals North America, Inc.
  The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.
  
  Patent expiration dates:
  
  
  • February 1, 2027
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Process for preparing malathion for pharmaceutical use
  Patent 7,977,324
  Issued: July 12, 2011
  Inventor(s): Gutman; Daniella & Baidussi; Wael
  Assignee(s): Taro Pharmaceuticals North America, Inc.
  The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.
  
  Patent expiration dates:
  
  
  • August 14, 2026
    
    ✓ 
    Drug product
  
  

See also...

• Ovide Consumer Information (Wolters Kluwer)
• Ovide Consumer Information (Cerner Multum)
• Ovide Topical Advanced Consumer Information (Micromedex)
• Ovide AHFS DI Monographs (ASHP)
• Malathion Consumer Information (Wolters Kluwer)
• Malathion topical Consumer Information (Cerner Multum)
• Malathion Topical Advanced Consumer Information (Micromedex)
• Malathion AHFS DI Monographs (ASHP)